Targeting the EWS-FLI1 transcription factor in Ewing sarcoma

R. Tancredi, A. Zambelli, G. A. Daprada, V. Fregoni, L. Pavesi, A. Riccardi, S. Burdach, P. J. Grohar, M. D'Incalci

Research output: Contribution to journalArticle

Abstract

Purpose: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. This combination was evaluated in Ewing sarcoma patient who was progressing with standard therapies. Methods: Trabectedin was given as a 24-h iv infusion on day 1 at the dose of 1 mg/sqm, and irinotecan 75 mg/sqm on day 2 and then on days 2 and 4, every 3 weeks from the seventh course. Results: The therapy was well tolerated with transient hematological toxicity and transaminitis and induced stabilization of the disease lasting for 11 courses, with clinical improvement and marked reduction of the need for opioids. However, shortly before the 12th course, sudden death occurred, possibly due to cerebral stroke, presumably not related to the drug treatment. Conclusions: The encouraging clinical benefit observed with the combination and its good tolerability deserves further investigation in Ewing sarcoma.

Original languageEnglish
Pages (from-to)1317-1320
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume75
Issue number6
DOIs
Publication statusPublished - Mar 26 2015

Fingerprint

irinotecan
trabectedin
Ewing's Sarcoma
Transcription Factors
Drug therapy
Opioid Analgesics
Toxicity
Stabilization
Therapeutics
Sudden Death
Stroke
EWS-FLI fusion protein

Keywords

  • Combination therapy
  • Ewing sarcoma
  • EWS-FLI1
  • Irinotecan
  • Trabectedin
  • Transcription mechanism
  • Werner gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology
  • Medicine(all)

Cite this

Tancredi, R., Zambelli, A., Daprada, G. A., Fregoni, V., Pavesi, L., Riccardi, A., ... D'Incalci, M. (2015). Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemotherapy and Pharmacology, 75(6), 1317-1320. https://doi.org/10.1007/s00280-015-2726-7

Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. / Tancredi, R.; Zambelli, A.; Daprada, G. A.; Fregoni, V.; Pavesi, L.; Riccardi, A.; Burdach, S.; Grohar, P. J.; D'Incalci, M.

In: Cancer Chemotherapy and Pharmacology, Vol. 75, No. 6, 26.03.2015, p. 1317-1320.

Research output: Contribution to journalArticle

Tancredi, R, Zambelli, A, Daprada, GA, Fregoni, V, Pavesi, L, Riccardi, A, Burdach, S, Grohar, PJ & D'Incalci, M 2015, 'Targeting the EWS-FLI1 transcription factor in Ewing sarcoma', Cancer Chemotherapy and Pharmacology, vol. 75, no. 6, pp. 1317-1320. https://doi.org/10.1007/s00280-015-2726-7
Tancredi R, Zambelli A, Daprada GA, Fregoni V, Pavesi L, Riccardi A et al. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemotherapy and Pharmacology. 2015 Mar 26;75(6):1317-1320. https://doi.org/10.1007/s00280-015-2726-7
Tancredi, R. ; Zambelli, A. ; Daprada, G. A. ; Fregoni, V. ; Pavesi, L. ; Riccardi, A. ; Burdach, S. ; Grohar, P. J. ; D'Incalci, M. / Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. In: Cancer Chemotherapy and Pharmacology. 2015 ; Vol. 75, No. 6. pp. 1317-1320.
@article{a1f8b750fcec4f39880316f28d0b4a56,
title = "Targeting the EWS-FLI1 transcription factor in Ewing sarcoma",
abstract = "Purpose: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. This combination was evaluated in Ewing sarcoma patient who was progressing with standard therapies. Methods: Trabectedin was given as a 24-h iv infusion on day 1 at the dose of 1 mg/sqm, and irinotecan 75 mg/sqm on day 2 and then on days 2 and 4, every 3 weeks from the seventh course. Results: The therapy was well tolerated with transient hematological toxicity and transaminitis and induced stabilization of the disease lasting for 11 courses, with clinical improvement and marked reduction of the need for opioids. However, shortly before the 12th course, sudden death occurred, possibly due to cerebral stroke, presumably not related to the drug treatment. Conclusions: The encouraging clinical benefit observed with the combination and its good tolerability deserves further investigation in Ewing sarcoma.",
keywords = "Combination therapy, Ewing sarcoma, EWS-FLI1, Irinotecan, Trabectedin, Transcription mechanism, Werner gene",
author = "R. Tancredi and A. Zambelli and Daprada, {G. A.} and V. Fregoni and L. Pavesi and A. Riccardi and S. Burdach and Grohar, {P. J.} and M. D'Incalci",
year = "2015",
month = "3",
day = "26",
doi = "10.1007/s00280-015-2726-7",
language = "English",
volume = "75",
pages = "1317--1320",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Targeting the EWS-FLI1 transcription factor in Ewing sarcoma

AU - Tancredi, R.

AU - Zambelli, A.

AU - Daprada, G. A.

AU - Fregoni, V.

AU - Pavesi, L.

AU - Riccardi, A.

AU - Burdach, S.

AU - Grohar, P. J.

AU - D'Incalci, M.

PY - 2015/3/26

Y1 - 2015/3/26

N2 - Purpose: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. This combination was evaluated in Ewing sarcoma patient who was progressing with standard therapies. Methods: Trabectedin was given as a 24-h iv infusion on day 1 at the dose of 1 mg/sqm, and irinotecan 75 mg/sqm on day 2 and then on days 2 and 4, every 3 weeks from the seventh course. Results: The therapy was well tolerated with transient hematological toxicity and transaminitis and induced stabilization of the disease lasting for 11 courses, with clinical improvement and marked reduction of the need for opioids. However, shortly before the 12th course, sudden death occurred, possibly due to cerebral stroke, presumably not related to the drug treatment. Conclusions: The encouraging clinical benefit observed with the combination and its good tolerability deserves further investigation in Ewing sarcoma.

AB - Purpose: Preclinical data indicate there is strong synergism of action against Ewing sarcoma in sequential treatment with trabectedin followed by irinotecan and it appears to be related to a selective blockade of the transcription factor EWS-FLI1. This combination was evaluated in Ewing sarcoma patient who was progressing with standard therapies. Methods: Trabectedin was given as a 24-h iv infusion on day 1 at the dose of 1 mg/sqm, and irinotecan 75 mg/sqm on day 2 and then on days 2 and 4, every 3 weeks from the seventh course. Results: The therapy was well tolerated with transient hematological toxicity and transaminitis and induced stabilization of the disease lasting for 11 courses, with clinical improvement and marked reduction of the need for opioids. However, shortly before the 12th course, sudden death occurred, possibly due to cerebral stroke, presumably not related to the drug treatment. Conclusions: The encouraging clinical benefit observed with the combination and its good tolerability deserves further investigation in Ewing sarcoma.

KW - Combination therapy

KW - Ewing sarcoma

KW - EWS-FLI1

KW - Irinotecan

KW - Trabectedin

KW - Transcription mechanism

KW - Werner gene

UR - http://www.scopus.com/inward/record.url?scp=84929711731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929711731&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2726-7

DO - 10.1007/s00280-015-2726-7

M3 - Article

C2 - 25809543

AN - SCOPUS:84929711731

VL - 75

SP - 1317

EP - 1320

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -